HOME >> BIOLOGY >> NEWS
Obscure Enzyme May Play Major Role In Heart Disease

NEW YORK, N.Y. and HAIFA, Israel, April 14, 1998 -- A little-known enzyme may play a significant role in preventing heart attack. A paper appearing April 15 in the prestigious Journal of Clinical Investigation, reports that paraoxonase, an enzyme present in the blood, prevents the oxidation of low-density lipoprotein or LDL, the "bad cholesterol" that is deposited in blood vessels and leads to coronary heart disease. The paper is by Professor Michael Aviram, a biochemist, head of the Lipid Research Laboratory, Faculty of Medicine at the Technion-Israel Institute of Technology and at Rambam Medical Center in Haifa, Israel.

"Paraoxonase is located in the blood on the HDL, the 'good' cholesterol, and it can break down oxidized LDL to non-harmful products," explains Aviram, adding that the discovery of this enzyme's activity opens a possible new route to prevention of heart diseases.

The real function of the enzyme has been something of a mystery since it was discovered more than 40 years ago. Its previously known function was to break down organophosphates, chemicals that are used as insecticides and poison gases. That activity was obviously not the complete story of paraoxonase, as humans do not normally contain these substances in their blood, Aviram realized.

Since the major focus of his past research has been the study of the mechanisms by which oxidized cholesterol and other oxidized lipids accumulate in arterial wall cells, leading to blockage of arteries and formation of atherosclerotic lesions, he decided to study the effect of the enzyme on oxidized lipids. Researchers had previously found a very strong inverse relationship between the activity of paraoxonase in the blood and the risk of heart disease. Lower activity is associated with higher risk. The present study helps us understand the mechanism behind that relationship.

In experiments with a
'"/>

Contact: Martha Molnar
martha@ats.org
(212) 307-2580
American Society for Technion - Israel Institute of Technology
15-Apr-1998


Page: 1 2 3

Related biology news :

1. Colorado State Scientists Tackle Genetic Makeup Of Obscure Bacteria
2. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
3. Enzyme activation appears key in helping internal clock tell night from day
4. Enzyme fully degrades mad cow disease prion
5. Enzyme revealed that is key to funguss ability to breach immune system
6. Enzyme discovery sheds light on causes of rare disease, cancer
7. Enzyme could overcome industrial bleaching waste problems
8. Enzyme controls good cholesterol
9. Enzyme discovery to benefit homeland security, industry
10. Enzyme could aid cancer fight
11. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Obscure Enzyme May Play Major Role Heart Disease

(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/19/2015)... 19, 2015  VOXX International Corporation (Nasdaq: ... into a Definitive Agreement to purchase the assets, ... market leader EyeLock through an acquiring entity.  Upon ... controlling interest in the acquiring entity. The closing ... due diligence.  Expanding on its existing supply chain ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... HONG KONG , Aug. 26, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... Holdings Limited ("MO2"), an entity wholly owned by Mr. ... the Company, has acquired the outstanding shares (the "Shares") ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, ... new business relationships with local sponsors in southern California. The Clinical Trial Management Expert ... development processes and regulatory pathways., , Stem Cell Meeting ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new optical ... is described by University of Illinois researchers in the Journal of Biomedical ... In “ Breast cancer diagnosis using spatial light interference microscopy ,” published 20 ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
Cached News: